Madrid, a two-time survivor of Stage 4 cancer, weaves together his life experiences – including his Italian heritage, the power of family connection, and effective mindset techniques – into an ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

On this Valentine's Day, a couple recalls everything they had to overcome from long distance to three cancer diagnoses over ...

A spokesperson for the charity said as symptoms can be vague, pancreatic cancer is difficult to diagnose at an early stage.

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a ...

Diabetes was associated with an increased risk of pancreatic cystic neoplasms (PCNs), with longer disease duration linked to progressively higher risk, according to a nationwide population-based ...

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

NovoCure (NVCR) stock rose 29% Thursday on early FDA approval for Optune Pax pancreatic cancer device, prompting H.C. Wainwright to raise target to $47.

NovoCure shares are popping Thursday following a major FDA approval that sent the stock soaring nearly 30% in Wednesday's ...

A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.